| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.053 | 0.8 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |